Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

by Zacks Equity Research

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

by Zacks Equity Research

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

by Zacks Equity Research

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

Yashwardhan Jain headshot

Where Are Biotech ETFs Headed After Q4 Earnings?

by Yashwardhan Jain

Look into how Biotech ETFs performed after Q4 earnings.

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

by Zacks Equity Research

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.

Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings

by Zacks Equity Research

The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -6.65% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AptarGroup (ATR) Inks Deal to Create Digital Health Solutions

by Zacks Equity Research

AptarGroup (ATR) enters an enterprise agreement with Biogen to create digital health solutions for neurological and rare diseases.

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Biogen Inc. (BIIB) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the most recent trading session, Biogen Inc. (BIIB) closed at $240.30, indicating a -0.1% shift from the previous trading day.

Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.

Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

by Zacks Equity Research

Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

by Zacks Equity Research

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.

Biogen Inc. (BIIB) Laps the Stock Market: Here's Why

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.

Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

by Zacks Equity Research

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.

Biogen Inc. (BIIB) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.

Biogen Inc. (BIIB) Stock Moves -0.37%: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $245.27, moving -0.37% from the previous trading session.